Weiting Liang, Zhijun Guo, Yunhui Zhang, Ning Yang, Chenchen Guo, Tao Liu, Hongbing Huang, Zhuojia Chen
INTRODUCTION: Cadonilimab (AK104) is an innovative human programmed cell death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody. Compared with the combination therapy of PD-1 and CTLA-4 blockers, less cellular toxicity of cadonilimab was significantly manifested. As one of the characteristic adverse effects of cadonilimab, infusion-related reactions (IRRs) represent fever, chills, rash, decreased blood pressure, and other symptoms. CASE PRESENTATION: Here, we documented seven cases of IRRs after the administration of cadonilimab...
2024: Case Reports in Oncology